BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Delrue M, Baylatry MT, Joly AC, Corre E, Marjanovic Z, El-Khoury-Hanna N, Féger F, Suner L, Veyradier A, Stépanian A, Coppo P. Efficacy of subcutaneous preemptive rituximab in immune-mediated thrombotic thrombocytopenic purpura: Experience from the first 12 cases. Am J Hematol 2021;96:E26-9. [PMID: 33068040 DOI: 10.1002/ajh.26022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Graça NAG, Joly BS, Voorberg J, Vanhoorelbeke K, Béranger N, Veyradier A, Coppo P. TTP: From empiricism for an enigmatic disease to targeted molecular therapies. Br J Haematol 2022. [PMID: 35146746 DOI: 10.1111/bjh.18040] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Poullin P. [Treatment of immune-mediated thrombotic thrombocytopenic purpura: A decisive turning point]. Transfus Clin Biol 2021;28:380-5. [PMID: 34464709 DOI: 10.1016/j.tracli.2021.08.347] [Reference Citation Analysis]
3 Lemiale V, Valade S, Mariotte E. Unresponsive Thrombotic Thrombocytopenic Purpura (TTP): Challenges and Solutions. Ther Clin Risk Manag 2021;17:577-87. [PMID: 34113115 DOI: 10.2147/TCRM.S205632] [Cited by in F6Publishing: 3] [Reference Citation Analysis]